



**THE FOUNDATION  
FOR SECURE  
MARKETS®**

#59278

**Date:** June 30, 2026

**Subject:** Quince Therapeutics, Inc. - Settlement Update  
Adjusted Option Symbol: QNCX1  
Date: 06/30/2026  
\* \* \* Effective Immediately \* \* \*

Effective on June 29, 2026, settlement of QNCX1 options exercise/assignment activity was subject to broker to broker settlement (see OCC Information Memo #59266). Quince Therapeutics, Inc. (QNCX) underwent a reverse split effective June 30, 2026 (see OCC Information Memo #59257). QNCX shares (CUSIP 22053A305) are now eligible for Continuous Net Settlement ("CNS") at the National Securities Clearing Corporation ("NSCC"). As a result, all exercise and assignment activity for QNCX1 options as of June 30, 2026 and thereafter for QNCX1 options will no longer be subject to broker to broker settlement and will settle through NSCC.

Any existing broker to broker obligations on QNCX exercise and assignment on June 29, 2026 will remain subject to broker to broker settlement.

The deliverable for QNCX1 options will remain the underlying 1 Quince Therapeutics, Inc. Common Share.

#### **Disclaimer**

This Information Memo provides an unofficial summary of the terms of corporate events affecting listed options or futures prepared for the convenience of market participants. OCC accepts no responsibility for the accuracy or completeness of the summary, particularly for information which may be relevant to investment decisions. Option or futures investors should independently ascertain and evaluate all information concerning this corporate event(s).

The determination to adjust options and futures and the nature of any adjustment is made by OCC pursuant to Chapter 28 (XXVIII) of OCC's Rules. For both options and futures, each adjustment decision is made on a case by case basis. Adjustment decisions are based on information available at the time and are subject to change as additional information becomes available or if there are material changes to the terms of the corporate event(s) occasioning the adjustment.

**ALL CLEARING MEMBERS ARE REQUESTED TO IMMEDIATELY ADVISE ALL BRANCH OFFICES AND CORRESPONDENTS ON THE ABOVE.**

For questions regarding this memo, please email the Investor Education team at [options@theocc.com](mailto:options@theocc.com).

Clearing Member Firms of OCC may contact Member Services at 1-800-544-6091 or, within Canada, at 1-800-424-7320, or email [memberservices@theocc.com](mailto:memberservices@theocc.com).